PMID- 31422113
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20200629
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 148
DP  - 2019 Oct
TI  - Strategies of targeting pathological stroma for enhanced antitumor therapies.
PG  - 104401
LID - S1043-6618(19)30681-4 [pii]
LID - 10.1016/j.phrs.2019.104401 [doi]
AB  - Cancer associated fibroblasts (CAFs) and the derived stromal components 
      constitute specific pathological stroma in desmoplastic tumors, which not only 
      hinder the distribution of drugs/nano-agents in tumors but also reduce the 
      sensibility of tumor cells to standard therapeutics. Consequently, pathological 
      stroma has gradually been termed potential target for antitumor therapy. However, 
      opposite outcomes have been observed to occur with the same strategy in different 
      tumor models and no general principles have been adopted due to the heterogeneity 
      and adaptivity of dynamic stroma, in which case diversified strategies for 
      antitumor therapies are urgent. In this review, we summarize the origins and 
      characterizations of pathological stroma and describe their critical influence on 
      tumor's responsiveness to oncotherapy. The design of combinational antitumor 
      strategies and stroma targeting drug delivery systems (DDSs) are also discussed 
      in detail. Collectively, the main purpose of this review is to improve our 
      understanding of the roles of stroma in tumor progression and provide new 
      insights for targeting pathological stroma.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Zhu, Yun
AU  - Zhu Y
AD  - Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University 
      Medical School, Nanjing, Jiangsu, 210008, People's Republic of China; Ocean 
      College, Zhejiang University, 1 Zheda Road, Zhoushan, 316021, People's Republic 
      of China.
FAU - Yu, Fangying
AU  - Yu F
AD  - College of Pharmaceutical Science, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, 310058, People's Republic of China.
FAU - Tan, Yanan
AU  - Tan Y
AD  - Ocean College, Zhejiang University, 1 Zheda Road, Zhoushan, 316021, People's 
      Republic of China.
FAU - Yuan, Hong
AU  - Yuan H
AD  - College of Pharmaceutical Science, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, 310058, People's Republic of China.
FAU - Hu, Fuqiang
AU  - Hu F
AD  - College of Pharmaceutical Science, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, 310058, People's Republic of China; Ocean College, Zhejiang University, 
      1 Zheda Road, Zhoushan, 316021, People's Republic of China. Electronic address: 
      hufq@zju.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190815
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology/*therapeutic use
MH  - Cancer-Associated Fibroblasts/drug effects/pathology
MH  - Disease Progression
MH  - Drug Delivery Systems/methods
MH  - Humans
MH  - Neoplasms/*drug therapy/*pathology
MH  - Tumor Microenvironment/drug effects
OTO - NOTNLM
OT  - CAFs
OT  - Combinational therapies
OT  - Drug delivery system
OT  - Stroma
OT  - Tumor microenvironment
EDAT- 2019/08/20 06:00
MHDA- 2020/07/01 06:00
CRDT- 2019/08/19 06:00
PHST- 2019/04/16 00:00 [received]
PHST- 2019/07/24 00:00 [revised]
PHST- 2019/08/13 00:00 [accepted]
PHST- 2019/08/20 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2019/08/19 06:00 [entrez]
AID - S1043-6618(19)30681-4 [pii]
AID - 10.1016/j.phrs.2019.104401 [doi]
PST - ppublish
SO  - Pharmacol Res. 2019 Oct;148:104401. doi: 10.1016/j.phrs.2019.104401. Epub 2019 
      Aug 15.